Lantheus Holdings, Inc. (NASDAQ:LNTH) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET

Company Participants

Mark Kinarney - Vice President of Investor Relations
Brian Markison - Chief Executive Officer
Paul Blanchfield - President
Bob Marshall - Chief Financial Officer

Conference Call Participants

Anthony Petrone - Mizuho Financial Group
Roanna Ruiz - Leerink Partners LLC
Richard Newitter - Truist Securities
Larry Solow - CJS Securities
Yuan Zhi - B. Riley
Justin Walsh - Jones Trading
Andy Hsieh - William Blair
Kemp Dolliver - Brookline Capital Markets

Operator

Good morning. Welcome to the Lantheus First Quarter 2024 Conference Call. All lines have been placed on mute. This call is being recorded and a replay will be available in the Investors section of the company's website approximately two hours after the completion of the call and will be archived for at least 30 days.

I will now turn the call over to Mark Kinarney, Vice President of the Investor Relations. Mark?

Mark Kinarney

Thank you. Good morning and welcome to today's call. With me today are Brian Markison, our CEO; Paul Blanchfield, our President; and Bob Marshall, our Chief Financial Officer. We will begin the call with prepared remarks and then open the call for Q&A. This morning, we issued a press release which was furnished to the Securities and Exchange Commission under Form 8-K reporting our first quarter 2024 results. The release and today's slide presentation are in the Investors section of our website at lantheus.com.

Any comments made during our call could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties. Discussions during the call will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is also included in the Investors section of our website.

It is my pleasure to now turn the call over to our CEO, Brian.

Brian Markison

Thank you, Mark and good morning everyone. This marks my first earnings call as CEO of Lantheus, and I am delighted to be here to lead this incredible team. I began my career as a pharmaceutical sales rep and have more than 40 years of experience. Throughout my career I have successfully led commercial efforts in numerous therapeutic categories, including oncology and immunology across major global markets. Having served most recently as the Chair of the Board and a Member of the Board since 2012, I have a deep understanding of Lantheus and the radiopharmaceutical industry and I'm committed to partnering with our exceptional leadership team to enhance the vision, strategy, and execution necessary to remain the leading radiopharmaceutical focused company.